Galectin Therapeutics Announces First Patient Dosed In Second Cohort Of Phase 1 Trial Of GR-MD-02 For NASH With Advanced Fibrosis
4/17/2014 9:27:45 AM
NORCROSS, Ga., April 17, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that the first patient in cohort 2 of its Phase 1 clinical trial of GR-MD-02 in patients with NASH with advanced fibrosis has been successfully dosed with 4 mg/kg, which is double the dose given in cohort 1. Cohort 2, as with all phases of the clinical trial, was initiated in full compliance with the rules, regulations, and specific conditions set forth by the U.S. Food and Drug Administration (FDA) for this Phase 1 clinical trial.
Help employers find you! Check out all the jobs and post your resume.
comments powered by